RAPT Therapeutics, Inc. (RAPT) Covered Calls

You can sell covered calls on RAPT Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for RAPT (prices last updated Fri 4:16 PM ET):

RAPT Therapeutics, Inc. (RAPT) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
1.10 -0.18 1.09 1.17 993K - 0.0
Covered Calls For RAPT Therapeutics, Inc. (RAPT)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Dec 20 2.5 0.05 1.12 4.5% 45.6%
Jan 17 2.5 0.00 1.17 0.0% 0.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.